Cusatuzumab is a humanized anti-CD70 monoclonal antibody. Cusatuzumab was shown to eliminate leukemia stem cells (LSCs) in vitro and in xenotransplantation experiments, which triggers gene signatures related to myeloid differentiation and apoptosis.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.